Administration of estrogen replacement therapy (ERT) to hysterectomized postmenopausal women decreases the incidences of breast cancer. Though paradoxical because estrogen is recognized to stimulate breast cancer growth, laboratory data support a mechanism of estrogen-induced apoptosis under the correct environmental circumstances. Long-term antiestrogen treatment or estrogen deprivation causes the eventual development and evolution of antihormone resistance. Cell populations emerge with a vulnerability, as estrogen is no longer a survival signal but is an apoptotic trigger. The antitumor effect of ERT in estrogen-deprived postmenopausal women is consistent with laboratory models.
Introduction
It is widely held that estrogen can be carcinogenic in breast tissue (1) and is the "fuel for the fire" to stimulate the growth of estrogen receptor (ER)−positive breast cancer cells (2) . This knowledge, supported by an enormous body of laboratory data, provides the conceptual basis for the successful development of antihormonal strategies to treat breast cancer (3) . Selective ER modulators (SERMs), e.g. tamoxifen, block estrogen-stimulated tumor growth at the ER, and aromatase inhibitors prevent peripheral estrogen synthesis in postmenopausal patients, thereby creating estrogen deprivation to stop tumor growth (3) . The successful treatment strategy for breast cancer with SERMs was subsequently translated into reducing the risk of breast cancer in high-risk women. SERMs are available to reduce the incidence of breast cancer in pre-and postmenopausal (tamoxifen) or postmenopausal (raloxifene) women (4) (5) (6) . As predicted by the mechanism of action of SERMs as anticancer agents, only ER-positive breast cancer is reduced.
In practice, preventing estrogen action prevents breast tumor initiation and growth.
Paradoxically, the recent analysis of estrogen replacement therapy (ERT) in the Women's Health Initiative (WHI) trial in hysterectomized women (7) actually showed a decrease in invasive breast cancer, which was sustained for 5 years after ERT was stopped. This result seems to run counter to the perceived wisdom of the role of estrogen in breast carcinogenesis.
When the WHI was initiated in 1993, their present clinical result of a reduction in breast cancer was unanticipated (7) but is consistent nevertheless with parallel laboratory studies completed over the past 20 years. Estrogen-induced apoptosis is a plausible molecular mechanism to support an antitumor action of physiologic estrogen (8) . The key to our understanding of estrogen-induced apoptosis is the finding that breast cancer cell populations adapt to estrogen deprivation, but these populations are dynamic, and resistance to estrogen deprivation evolves over time (5 years) . This evolution of resistance to estrogen deprivation causes a reconfiguration of cellular survival pathways, which in turn exposes a vulnerability of breast cancer cell survival. Physiologic estrogen causes apoptosis and does not act as a survival signal (8) .
We will weigh the laboratory and clinical evidence to support the proposition that physiologic estrogen can cause apoptosis in breast cancer cells following long-term estrogen deprivation. Our objective is to make a case based on scientific observations to support our proposition that nascent breast cancer cells could have the same apoptotic response to ERT after estrogen deprivation caused by menopause. We will present the evidence in chronological order (Box 1).
Evidence from the Historical Use of Estrogens to Treat Metastatic Breast Cancer
The application of high-dose estrogen therapy for the treatment of metastatic breast cancer was the first use of a chemical therapy to treat any cancer successfully (9) . Estrogen therapy became the standard of care to treat metastatic breast cancer in postmenopausal patients until the introduction of tamoxifen (late 1970s in the U.S.), a nonsteroidal antiestrogen (10) . (18, 19) . These data provided a scientific rationale for subsequent clinical studies.
Estrogen Induces Apoptosis in Estrogen-deprived ER-positive Breast Cancer Cell Lines
Song and co-workers (20) first showed in cell culture that high concentrations of estrogen could induce cellular apoptosis directly through a FAS/FASL pathway. However, the discovery that physiologic concentrations of estradiol could induce apoptosis (21) in both cell culture and animal models was the advance pertinent to the clinical observation that ERT reduces the incidence of breast cancer in postmenopausal women (7) . This is now a consistent experimental observation with new knowledge emerging about the molecular mechanisms of estrogen-induced apoptosis. Figure 1 summarizes much of the current data on molecular mechanisms of estrogen- 
induced apoptosis, the topic of a forthcoming mini-review in Cancer Prevention Research later this year.
Despite the significant body of laboratory data to support the proposition that physiologic estrogen can induce apoptosis in long-term estrogen-deprived breast cancer cells, only the translation to patients tests the veracity of the experimental approach as a conversation with nature and a general principle.
Current Evaluation of Estrogen to Treat Acquired Antihormone Resistance in

Metastatic Breast Cancer
Lonning and co-workers (22) studied the efficacy of high dose of DES on the responsiveness of metastatic breast cancer following exhaustive treatment with antihormone therapies (tamoxifen, aromatase inhibitors, etcetera). A remarkable 4 of 32 patients had complete responses (22), and one patient, who was treated for 5 years, had no recurrence of her disease 6 years after stopping DES (23) . The question, however, is whether physiologic estrogen has efficacy as an antitumor agent in the appropriately prepared estrogen-deprived breast tumor. Ellis and co-workers (24) addressed this question and found an equivalent clinical benefit for high (30 mg daily) and low (6 mg daily) dose of estradiol in metastatic breast cancer patients who had failed aromatase inhibitor therapy, i.e., long-term estrogen deprivation. Their clinical advance was that low-dose estrogen was as efficacious as high-dose estrogen for antitumor therapy in breast cancer (for the appropriate tumor that had been estrogen deprived), but there were fewer side effects with low-dose therapy. The target, estrogen-deprived breast cancer, is vulnerable to physiologic estrogen. Jordan, Ford--8
The Extrapolation of the Concept that Physiologic Estrogen Kills Breast Cancer to Adjuvant Antihormone Therapy
The result from the WHI Trial of ERT in hysterectomized women (7), which showed a sustained reduction in the incidence of breast cancer, provides additional evidence that the strategy to decipher the mechanism of physiologic estrogen to induce apoptosis (8, 25, 26) has significance for both treatment and prevention. Indeed, the idea that a woman's own estrogen was responsible for enhanced survivorship by causing apoptosis of the appropriately prepared and vulnerable micrometastases (16) 
Jordan, Ford--9 but different epigenetic events based on the well-established property of cancer cells to be able to adapt to any environment and survive remains true. As the WHI study of ERT shows (7) 
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